By modulating multiple classical oncogenic pathways such as PTEN/PI3K/AKT and SPRY/RAF/ERK, it regulates critical processes central to cancer progression such as EMT [42,43,56,57], chemoresistance [46,59,77], and metastasis [63,71]. This evidence concerns the gene PIK3CG and cancer.